CD8A and neoplasm: Although all the treatment groups, includingR.E­(IT), R.E@MN and aPD-1, showed a significant increase in CD8+ T cell to both the tumor and TDLN, the combination of R.E@MNwith aPD-1 resulted in a remarkably higher infiltration of CD8+ T cells in both sites, compared to the monotherapies(Figure A,B).